TerminatedPhase 3

A Study Of The Efficacy And Safety Of Anidulafungin Vs. Fluconazole In The Treatment Of Patients With Candidemia And/Or Other Forms Of Invasive Candidiasis

Stopped: See termination reason in detailed description.

China17 participantsStarted 2010-12

Plain-language summary

In the treatment of patients with candidemia and/or other forms of invasive candidiasis , Anidulafungin is at least as effective and safe as Fluconazole.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Presence of candidemia or invasive candidiasis. * Presence of one or more of signs and symptoms of acute fungal infection. Exclusion Criteria: * Subjects who received greater than 48 hours of systemic antifungal treatment for the Candida infection for which they will be enrolled. * Subjects with hypersensitivity to echinocandins or azole therapy or drug excipients.

What they're measuring

Percentage of Participants With Global Response at End of Intravenous Treatment (EOIT)

Timeframe: End of Intravenous Treatment (Up to Day 42)

Trial details

NCT IDNCT01176058

SponsorPfizer

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2011-11

Results submitted2012-10-29

View on ClinicalTrials.gov More Candidemia trials